The growing tension between the innovator and generic drug industries over access to branded products for bioequivalence testing is moving beyond the framework of restricted distribution programs under Risk Evaluation and Mitigation Strategies.
Legal disputes are on the rise in which generic drug manufacturers assert the brand company has used a voluntary restricted distribution program to prohibit access to the reference listed drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?